N-acetylcysteine and celecoxib lessen cadmium cytotoxicity which is associated with cyclooxygenase-2 up-regulation in mouse neuronal cells.
In many neurodegenerative disorders, aggregates of ubiquitinated proteins are detected in neuronal inclusions, but their role in neurodegeneration remains to be defined. To identify intracellular mechanisms associated with the appearance of ubiquitin-protein aggregates, mouse neuronal HT4 cells were treated with cadmium. This heavy metal is a potent cell poison that mediates oxidative stress and disrupts the ubiquitin/proteasome pathway. In the current studies, the following intracellular events were found to be also induced by cadmium: (i) a specific rise in cyclooxygenase-2 (COX-2) gene expression but not COX-1; (ii) an increase in the extracellular levels of the proinflammatory prostaglandin E2, a product of COX-2; and (iii) production of 4-hydroxy-2-nonenal-protein adducts, which result from lipid peroxidation. In addition, cadmium treatment led to the accumulation of high molecular weight ubiquitin-COX-2 conjugates and perturbed COX-2 glycosylation. The thiol-reducing antioxidant N-acetylcysteine, and, to a lesser extent, the COX-2 inhibitor celecoxib, attenuated the loss of cell viability induced by cadmium demonstrating that oxidative stress and COX-2 activation contribute to cadmium cytotoxicity. These findings establish that disruption of the ubiquitin/proteasome pathway is not the only event triggered by cadmium. This oxidative stressor also activates COX-2 function. Both events could be triggered by formation of 4-hydroxy-2-nonenal as a result of cadmium-induced lipid peroxidation. Proinflammatory responses stimulated by oxidative stressors that mimic the cadmium effects may, therefore, be important initiators of the neurodegenerative process and exacerbate its progress.
Figueiredo-Pereira
Maria E
ME
Department of Biological Sciences, Hunter College of City University of New York, New York 10021, USA. pereira@genectr.hunter.cuny.edu
Li
Zongmin
Z
Jansen
Marlon
M
Rockwell
Patricia
P
D000111:Acetylcysteine / Q000494:pharmacology*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001483:Base Sequence; D002104:Cadmium / Q000633:toxicity*; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D003546:Cysteine Endopeptidases / Q000378:metabolism; D017931:DNA Primers; D015232:Dinoprostone / Q000378:metabolism; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D009097:Multienzyme Complexes / Q000378:metabolism; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics / Q000378:metabolism*; D046988:Proteasome Endopeptidase Complex; D011720:Pyrazoles; D013449:Sulfonamides / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D025801:Ubiquitin / Q000378:metabolism; D015854:Up-Regulation
D000975:Antioxidants; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D017931:DNA Primers; D007527:Isoenzymes; D009097:Multienzyme Complexes; D011720:Pyrazoles; D013449:Sulfonamides; D025801:Ubiquitin; D002104:Cadmium; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D000068579:Celecoxib; D015232:Dinoprostone; D000111:Acetylcysteine